The dismal outlook is the latest setback for Novavax that has also faced manufacturing hurdles and regulatory delays amid competition with market leaders Pfizer <PFE.N> and Moderna <MRNA.O>.
Neutral
Neutral
Moderna
Neutral
Neutral
Pfizer
Negative
Negative
Novavax